Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 3:16 PM
Ignite Modification Date:
2025-12-25 @ 1:37 PM
NCT ID:
NCT03524092
Pre Assignment Details:
This study was designed to evaluate the safety and efficacy of mirikizumab (miri) in achieving remission at Week (Wk) 40 in participants who completed the 12-week induction study I6T-MC-AMAN (NCT03518086) as clinical responders to mirikizumab. Results for maximum extended enrollment (ME2) participants will be posted after the study completion.
Recruitment Details:
A total of 1177 Participants enrolled in the study of which 716 participants entered to Blinded Maintenance Period as Induction Responder (IR) and 461 participants entered into open label extended Induction period as Induction Nonresponders.
Study:
NCT03524092
Study Brief:
Results Section:
NCT03524092